CytomX Therapeutics, Inc.
About CytomX Therapeutics, Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $76.2M
- Net income
- -$17.4M
- Total assets
- $151.6M
- Market cap
- $653.1M
- Operating margin
- -29.3%
- Net margin
- -22.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $76.2M
- Operating expenses
- $98.6M
- Operating income
- -$22.4M
- Income tax
- $238.0K
- Net income
- -$17.4M
Balance sheet
- Total assets
- $151.6M
- Current assets
- $143.9M
- Total liabilities
- $52.6M
- Current liabilities
- $46.6M
- Shareholders’ equity
- $99.0M
Cash flow
- Operating cash flow
- -$75.6M
- Investing cash flow
- -$59.7M
- Financing cash flow
- $110.4M
- Net cash flow
- -$24.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $653.1M
- Shares outstanding
- 222.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.4M in FY2025.
- Revenue grew 10% from FY2021 to FY2025.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CytomX Therapeutics, Inc..
Write a review
News about CytomX Therapeutics, Inc.
News & sentiment via Polygon.io
